BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

SeraCare Life Sciences, Inc. (SRLS) Introduces IVD Labeled ACCURUN Controls for Women's Health


11/12/2013 12:01:21 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MILFORD, Mass.
, Nov. 12, 2013 /PRNewswire/ -- SeraCare Life Sciences, a manufacturer of life sciences tools, bulk plasma, and quality controls for diagnostic companies and clinical laboratories, announced availability of IVD labeled ACCURUN® controls for Women's Health. These Human Papilloma Virus (HPV) and Chlamydia trachomatis/Neisseria gonorrhea (Ct/Ng) offerings are cellular-based independent controls used by clinical laboratories to challenge their in vitro diagnostic assays.

(Photo: http://photos.prnewswire.com/prnh/20131112/NE14697)

"Our investment in making these controls available as IVD labeled products is an indicator of SeraCare's focus on the Women's Health market," said Vince Smith, director of the Clinical Lab business unit at SeraCare. "Our ACCURUN products are well-regarded in the industry as whole process controls, providing a rigorous challenge to the entire testing procedure."

ACCURUN 372 HPV DNA positive controls challenge HPV tests from extraction through amplification and detection. They are cellular-based controls formulated for use with laboratory tests that detect HPV DNA in human cervical samples. ACCURUN 341 Ct/Ng controls closely mimic human samples due to whole organism structure and deliver convenient plug and play design for direct placement on the instrument.

About SeraCare Life Sciences
SeraCare, a portfolio company of Linden Capital Partners, works with diagnostics researchers, IVD manufacturers, and clinical laboratories to shape the future of medical diagnostics. Our innovative portfolio includes ACCURUN® quality controls, AccuTrak, AccuSpan, AccuSet and AccuVert panels, KPL antibodies and immunoassay reagents, SeraCon processed plasma, specialty human blood products, and Complete BioCollections materials. SeraCare helps bridge the gap between today's diagnostic solutions and tomorrow's emerging technologies.

About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden invests in middle market platforms in the medical products, specialty distribution, and services segments of healthcare.

Marsha Ann Marsh
SeraCare Life Sciences
+1 508.244.6400 ext. 6106
mmarsh@seracare.com

SOURCE SeraCare Life Sciences



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES